-transparent.png){kind=logo}
Cisplatin resistance remains poorly understood compared to other forms of anti-neoplastic drug resistance. In this report radiolabeled cisplatin and rapid separation techniques were used to compare drug uptake by L1210 leukemia cells that are sensitive (K25) or resistant (ZCR9) to cisplatin. Uptake of cisplatin by both cell lines was linear without saturation kinetics up to 100 microM. The resistant ZCR9 cells had 36-60% reduced drug uptake as compared to its sensitive parent line, K25. In contrast, there was no difference in the rate of efflux. We conclude that a decreased rate of uptake is one possible mechanism of cellular cisplatin resistance.
Related Publications
R A Hromas, and
J A North, and
C P Burns
December 1987,
Cancer research,
R A Hromas, and
J A North, and
C P Burns
October 1988,
Gan to kagaku ryoho. Cancer & chemotherapy,
R A Hromas, and
J A North, and
C P Burns
January 1987,
Cancer chemotherapy and pharmacology,
R A Hromas, and
J A North, and
C P Burns
July 1972,
Cancer research,
R A Hromas, and
J A North, and
C P Burns
November 1964,
Cancer research,
R A Hromas, and
J A North, and
C P Burns
January 1987,
Cancer letters,
R A Hromas, and
J A North, and
C P Burns
October 1988,
Cancer research,
R A Hromas, and
J A North, and
C P Burns
October 1972,
Biochemical pharmacology,
R A Hromas, and
J A North, and
C P Burns
February 1986,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
R A Hromas, and
J A North, and
C P Burns
December 1967,
Cancer research,
